Status:
UNKNOWN
Venetoclax in Combination With Standard Induction and Consolidation Chemotherapy in Newly Diagnosed Young AML Patients
Lead Sponsor:
Peking Union Medical College Hospital
Conditions:
Acute Myeloid Leukemia
Eligibility:
All Genders
18-59 years
Brief Summary
The goal of this observational study is to to evaluate the efficacy and safety of Venetoclax in combination with DA60(daunorubicin 60 mg/m2/d for 3 days, and cytarabine 100 mg/m2 every 12 h for 7 days...
Eligibility Criteria
Inclusion
- Newly diagnosed, morphologically documented AML based on the World Health Organization (WHO) 2016 classification.
- Age ≥ 18 years and ≤ 59 years
- Have been treat with the "venetoclax in combination with standard induction and consolidation chemotherapy" therapy, and in follow-up.
- Be comprehensive of the research, and able to provide informed consent.
Exclusion
- Diagnosis of acute promyelocytic leukemia (APL).
- Prior treatment for AML, except for: leukapheresis, hydroxyurea, and growth factor/cytokine.
- Unable to understand or participate.
Key Trial Info
Start Date :
January 21 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT06162325
Start Date
January 21 2022
End Date
December 31 2025
Last Update
December 8 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China, 100730